Category Archives: Mesenchymal Stem Cells

Xenograft in nude mice (Mesenchymal stem cells) By: Nigel Li … Continue reading →

Bill Anderson felt like he was in the best shape of his life when doctors diagnosed him with multiple sclerosis in 2001. The Harborcreek Township real estate agent's regular workouts were interrupted by a sudden numbness in his abdomen that radiated down to his feet. "I went to the emergency room and was later admitted to the hospital," said Anderson, now 49. "They did some tests and diagnosed me with relapsing-remitting multiple sclerosis. I was stunned." Anderson has fought MS for 13 years, giving as little ground as he can to the relentless disease. He still works full time but now walks with a cane or a walker when the terrain is uneven. His symptoms have worsened in recent years and traditional medications aren't helping him much. So Anderson is ready to take a drastic step: Spend $25,000 to travel to Panama for stem cell treatments. "I'm not going to lie down and let this disease take me down, when there may be something out there to help me," Anderson said. He is preparing to visit the Stem Cell Institute in Panama City in July and undergo intravenous injections of stem cells as a treatment for MS. The stem cells … Continue reading →

Stem cells have the unique ability to become any type of cell in the body. Given this, the possibility that they can be cultured and engineered in the laboratory makes them an attractive option for regenerative medicine. However, some conditions that are commonly used for culturing human stem cells have the potential to introduce contaminants, thus rendering the cells unusable for clinical use. These conditions cannot be avoided, however, as they help maintain the pluripotency of the stem cells. In a study published in Scientific Reports, a group from the RIKEN Center for Life Science Technologies in Japan has gained new insight into the role of CCL2, a chemokine known to be involved in the immune response, in the enhancement of stem cell pluripotency. In the study, the researchers replaced basic fibroblast growth factor (bFGF), a critical component of human stem cell culture, with CCL2 and studied its effect. The work showed that CCL2 used as a replacement for bFGF activated the JAK/STAT pathway, which is known to be involved in the immune response and maintenance of mouse pluripotent stem cells. In addition, the cells cultured with CCL2 demonstrated a higher tendency of colony attachment, high efficiency of cellular differentiation, … Continue reading →

treatment available for autism spectrum disorder After stem cell therapy treatment available for autism spectrum disorder parents of the child from London United Kingdom testifying most of the amazing improvements they saw after stem cell... By: Neurogen Brain and Spine Institute … Continue reading →

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukemia cells and suppress their growth. The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukemia immunotherapy. leukemia is characterized by the accumulation of cancer cells originating from blood cells, in the blood or bone marrow. Current treatments for leukemia largely involve chemotherapy to eradicate all cancer cells, followed by stem cell transplants to restore healthy blood cells in the patients. In a recent study reported in the Journal of Experimental Medicine (JEM) online, the team co-led by Dr Lucia Mori and Prof Gennaro De Libero identified a new class of lipids, methyl-lysophosphatidic acids (mLPA), which accumulate in leukemia cells. Following which, the team identified a specific group of immune cells, described as mLPA-specific T-cells that are capable of recognising the mLPA in the leukemia cells. The detection triggers an immune response that activates the T cells to kill the leukemia cells and limits cancer progression. The efficacy of the … Continue reading →

NEW YORK, June 18 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024 http://www.reportlinker.com/p02148733/Pharma-Leader-Series-Top-Stem-Cell-Technology-Companies-2014-2024.html Report Details Stem cell developers and producers - discover companies' R&D and revenue prospects Who are the top stem cell developers and producers? And what are their sales potentials? Visiongain's new report shows you their outlooks from 2014. There you discover therapies, sales results, trends, opportunities, and predictions of revenues. That way you find data and analysis on cellular technologies with potential to improve human medicine. Our study analyses 22 leading companies in the US, Europe, Israel, and Asia. There you hear how stem cell producers can gain and progress, discovering what's possible. Read on to see those organisations and find what their market could be worth. Forecasts and other data helping you stay ahead for those technologies and applications In our new study you find analytical profiles of 22 stem cell companies, and analyses of that overall industry. So you see results, research and development (R&D), growth rates, and revenue forecasting. Discover, from 2014, those firms' commercial prospects. Here is the original post: Pharma Leader Series: Top Stem Cell … Continue reading →

The Children's Medical Center Research Institute at UT Southwestern (CRI) has identified a biomarker that enables researchers to accurately characterize the properties and function of mesenchymal stem cells (MSCs) in the body. MSCs are the focus of nearly 200 active clinical trials registered with the National Institutes of Health, targeting conditions such as bone fractures, cartilage injury, degenerative disc disease, and osteoarthritis. The finding, published in the journal Cell Stem Cell on June 19, significantly advances the field of MSC biology, and if the same biomarker identified in CRI's studies with mice works in humans, the outlook for clinical trials that use MSCs will be improved by the ability to better identify and characterize the relevant cells. "There has been an increasing amount of clinical interest in MSCs, but advances have been slow because researchers to date have been unable to identify MSCs and study their normal physiological function in the body," said Dr. Sean Morrison, Director of the Children's Research Institute, Professor of Pediatrics at UT Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator. "We found that a protein known as leptin receptor can serve as a biomarker to accurately identify MSCs in adult bone marrow in … Continue reading →

PUBLIC RELEASE DATE: 9-Jun-2014 Contact: Lucia Lee NewsMedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine (New York June 9, 2014) -- A protein may be the key to maintaining the health of aging blood stem cells, according to work by researchers at the Icahn School of Medicine at Mount Sinai recently published online in Stem Cell Reports. Human adults keep stem cell pools on hand in key tissues, including the blood. These stem cells can become replacement cells for those lost to wear and tear. But as the blood stem cells age, their ability to regenerate blood declines, potentially contributing to anemia and the risk of cancers like acute myeloid leukemia and immune deficiency. Whether this age-related decline in stem cell health is at the root of overall aging is unclear. The new Mount Sinai study reveals how loss of a protein called Sirtuin1 (SIRT1) affects the ability of blood stem cells to regenerate normally, at least in mouse models of human disease. This study has shown that young blood stem cells that lack SIRT1 behave like old ones. With use of advanced mouse models, she and her team found that blood stem cells without adequate … Continue reading →

Patient Testimonial: Stem cell therapy for COPD Treatment in SERBIA http://www.placidway.com/profile/1617/ - Marko was treated for COPD with Stem Cell Therapy in Swiss Medica's Serbian Clinic. How the treatment effectiveness ... By: placidways … Continue reading →

Successful Fetal Stem Cell Therapy in Kyiv, Ukraine at EmCell via PlacidWay Watch Daniel's testimonial after undergoing successful Fetal Stem Cell Therapy at EmCell in Kyiv, Ukraine. By: placidways … Continue reading →